Brainstorm Cell Therapeutics I - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BCLI Nasdaq 8731 http://www.brainstorm-cell.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Brainstorm Cell Therapeutics I

BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update - Mar 30th, 2023 11:05 am
BCLI: FDA Grants Adcom for NurOwn®… - Mar 27th, 2023 1:15 pm
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS - Mar 27th, 2023 10:00 am
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update - Mar 21st, 2023 12:18 pm
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study - Jan 10th, 2023 12:00 pm
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023 - Jan 5th, 2023 12:30 pm
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer - Jan 4th, 2023 12:30 pm
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® - Dec 27th, 2022 11:00 am
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration - Dec 12th, 2022 12:00 pm
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen - Nov 17th, 2022 11:56 am
BCLI: Receives a Refusal to File Letter from the FDA for NurOwn® BLA… - Nov 17th, 2022 11:15 am
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More - Nov 16th, 2022 4:28 pm
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update - Nov 14th, 2022 12:05 pm
FDA Refuses To Accept BrainStorm Cell's Lead Candidate For Amyotrophic Lateral Sclerosis - Nov 10th, 2022 4:01 pm
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS - Nov 10th, 2022 1:30 pm
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update - Nov 7th, 2022 9:10 pm
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting - Nov 7th, 2022 11:00 am
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress - Oct 20th, 2022 10:00 am
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium - Oct 7th, 2022 4:00 pm
BCLI: Relvyrio™ Approval Shows FDA Flexibility for ALS Treatments… - Oct 4th, 2022 10:00 am